From T cell "exhaustion" to anti-cancer immunity

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1865, Issue 1, 2016, Pages 49-57

  Verdeil, Grégory ^a   Fuertes Marraco, Silvia A ^a   Murray, Timothy ^a   Speiser, Daniel E ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Cancer biology; Cancer immunotherapy; Clinical trials; Exhaustion; T cells; Tumor microenvironment

Indexed keywords

CD45RO ANTIGEN; IPILIMUMAB; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DISEASE RESISTANCE; GRAFT VERSUS LEUKEMIA EFFECT; HOST RESISTANCE; HUMAN; IMMUNOLOGICAL TOLERANCE; INNATE IMMUNITY; LYMPHOCYTE FUNCTION; MELANOMA; NONHUMAN; PRIORITY JOURNAL; T CELL EXHAUSTION; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; ANIMAL; GENETIC TRANSCRIPTION; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TRANSCRIPTION, GENETIC;

EID: 84958907358     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2015.06.007     Document Type: Article

References (106)

1. Fearon D.T., Manders P., Wagner S.D. Arrested differentiation, the self-renewing memory lymphocyte, and vaccination. Science (N. Y.) 2001, 293:248-250. 10.1126/science.1062589.
2. Zanetti M., Schoenberger S.P. Memory T cells. Pref. Adv. Exp. Med. Biol. 2010, 684:vii-ix.
3. Zhang N., Bevan M.J. CD8(+) T cells: foot soldiers of the immune system. Immunity 2011, 35:161-168. 10.1016/j.immuni.2011.07.010.
4. Gattinoni L., Klebanoff C.A., Restifo N.P. Paths to stemness: building the ultimate antitumour T cell. Nat. Rev. Cancer 2012, 12:671-684. 10.1038/nrc3322.
5. Graef P., Buchholz V.R., Stemberger C., Flossdorf M., Henkel L., Schiemann M., et al. Serial transfer of single-cell-derived immunocompetence reveals stemness of CD8(+) central memory T cells. Immunity 2014, 41:116-126. 10.1016/j.immuni.2014.05.018.
6. Fuertes Marraco S.A., Soneson C., Cagnon L., Gannon P.O., Allard M., Maillard S.A., et al. Long-lasting stem cell-like memory CD8+ T cells with a naïve-like profile upon yellow fever vaccination. Sci. Transl. Med. 2015, 7:282ra48. 10.1126/scitranslmed.aaa3700.
7. D.W.MD Best practice & research clinical haematology. Best Pract. Res. Clin. Haematol. 2013, 26:293-296. 10.1016/j.beha.2013.10.010.
8. Vyas P., Appelbaum F.R., Craddock C. Biology of blood and marrow transplantation. Biol. Blood Marrow Transplant. 2015, 21:8-15. 10.1016/j.bbmt.2014.10.026.
9. Walunas T.L., Lenschow D.J., Bakker C.Y., Linsley P.S., Freeman G.J., Green J.M., et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994, 1:405-413.
10. Krummel M.F., Allison J.P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 1995, 182:459-465.
11. Waterhouse P., Penninger J.M., Timms E., Wakeham A., Shahinian A., Lee K.P., et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science (N. Y.) 1995, 270:985-988.
12. Tivol E.A., Borriello F., Schweitzer A.N., Lynch W.P., Bluestone J.A., Sharpe A.H. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995, 3:541-547.
13. Leach D.R., Krummel M.F., Allison J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science (N. Y.) 1996, 271:1734-1736.
14. Callahan M.K., Wolchok J.D. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J. Leukoc. Biol. 2013, 94:41-53. 10.1189/jlb.1212631.
15. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363:711-723. 10.1056/NEJMoa1003466.
16. Robert C., Thomas L., Bondarenko I., O'Day S., Weber J., Garbe C., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 2011, 364:2517-2526. 10.1056/NEJMoa1104621.
17. Schadendorf D., Hodi F.S., Robert C., Weber J.S., Margolin K., Hamid O., et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J. Clin. Oncol. 2015, 10.1200/JCO.2014.56.2736.
18. Keir M.E., Butte M.J., Freeman G.J., Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 2008, 26:677-704. 10.1146/annurev.immunol.26.021607.090331.
19. Taube J.M., Anders R.A., Young G.D., Xu H., Sharma R., McMiller T.L., et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med. 2012, 4:127ra37. 10.1126/scitranslmed.3003689.
20. Iwai Y., Ishida M., Tanaka Y., Okazaki T., Honjo T., Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:12293-12297. 10.1073/pnas.192461099.
21. Dong H., Strome S.E., Salomao D.R., Tamura H., Hirano F., Flies D.B., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 2002, 8:793-800. 10.1038/nm730.
22. Robert C., Schachter J., Long G.V., Arance A., Grob J.-J., Mortier L., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 2015, 10.1056/NEJMoa1503093.
23. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012, 366:2443-2454. 10.1056/NEJMoa1200690.
24. Garon E.B., Rizvi N.A., Hui R., Leighl N., Balmanoukian A.S., Eder J.P., et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 2015, 10.1056/NEJMoa1501824.
25. Callahan M.K., Postow M.A., Wolchok J.D. CTLA-4 and PD-1 pathway blockade: combinations in the clinic. Front. Oncol. 2014, 4:385. 10.3389/fonc.2014.00385.
26. Naidoo J., Page D.B., Wolchok J.D. Immune modulation for cancer therapy. Br. J. Cancer 2014, 10.1038/bjc.2014.348.
27. Shin D.S., Ribas A. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?. Curr. Opin. Immunol. 2015, 33:23-35. 10.1016/j.coi.2015.01.006.
28. Wolchok J.D., Kluger H., Callahan M.K., Postow M.A., Rizvi N.A., Lesokhin A.M., et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 2013, 369:122-133. 10.1056/NEJMoa1302369.
29. Speiser D.E., Lienard D., Pittet M.J., Batard P., Rimoldi D., Guillaume P., et al. In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells. Eur. J. Immunol. 2002, 32:731-741. 10.1002/1521-4141(200203)32:3<731::AID-IMMU731>3.0.
30. Haanen J.B.A.G., Baars A., Gomez R., Weder P., Smits M., de Gruijl T.D., et al. Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer Immunol. Immunother. 2006, 55:451-458. 10.1007/s00262-005-0018-5.
31. Fridman W.-H., Pagès F., Sautes-Fridman C., Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 2012, 12:298-306. 10.1038/nrc3245.
32. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 2012, 366:883-892. 10.1056/NEJMoa1113205.
33. Romano E., Pradervand S., Paillusson A., Weber J., Harshman K., Muehlethaler K., et al. Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression. Clin. Cancer Res. 2013, 19:5749-5757. 10.1158/1078-0432.CCR-13-0661.
34. Schumacher T.N., Schreiber R.D. Neoantigens in cancer immunotherapy. Science (N. Y.) 2015, 348:69-74. 10.1126/science.aaa4971.
35. Gubin M.M., Zhang X., Schuster H., Caron E., Ward J.P., Noguchi T., et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014, 515:577-581. 10.1038/nature13988.
36. Yadav M., Jhunjhunwala S., Phung Q.T., Lupardus P., Tanguay J., Bumbaca S., et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 2014, 515:572-576. 10.1038/nature14001.
37. Herbst R.S., Soria J.-C., Kowanetz M., Fine G.D., Hamid O., Gordon M.S., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014, 515:563-567. 10.1038/nature14011.
38. Linnemann C., van Buuren M.M., Bies L., Verdegaal E.M.E., Schotte R., Calis J.J.A., et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat. Med. 2015, 21:81-85. 10.1038/nm.3773.
39. Rizvi N.A., Hellmann M.D., Snyder A., Kvistborg P., Makarov V., Havel J.J., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (N. Y.) 2015, 348:124-128. 10.1126/science.aaa1348.
40. Baitsch L., Fuertes Marraco S.A., Legat A., Meyer C., Speiser D.E. The three main stumbling blocks for anticancer T cells. Trends Immunol. 2012, 33:364-372. 10.1016/j.it.2012.02.006.
41. Allavena P., Mantovani A. Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin. Exp. Immunol. 2012, 167:195-205. 10.1111/j.1365-2249.2011.04515.x.
42. Gabrilovich D.I., Ostrand-Rosenberg S., Bronte V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 2012, 12:253-268. 10.1038/nri3175.
43. Devaud C., John L.B., Westwood J.A., Darcy P.K., Kershaw M.H. Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. OncoImmunology 2013, 2:e25961. 10.4161/onci.25961.
44. Swartz M.A. Immunomodulatory roles of lymphatic vessels in cancer progression. Cancer Immunol. Res. 2014, 2:701-707. 10.1158/2326-6066.CIR-14-0115.
45. Vignali D.A.A., Collison L.W., Workman C.J. How regulatory T cells work. Nat. Rev. Immunol. 2008, 8:523-532. 10.1038/nri2343.
46. Ostrand-Rosenberg S., Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 2009, 182:4499-4506. 10.4049/jimmunol.0802740.
47. Ostman A., Augsten M. Cancer-associated fibroblasts and tumor growth-bystanders turning into key players. Curr. Opin. Genet. Dev. 2009, 19:67-73. 10.1016/j.gde.2009.01.003.
48. Blackburn S.D., Shin H., Haining W.N., Zou T., Workman C.J., Polley A., et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 2009, 10:29-37. 10.1038/ni.1679.
49. Wherry E.J., Ha S.-J., Kaech S.M., Haining W.N., Sarkar S., Kalia V., et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 2007, 27:670-684. 10.1016/j.immuni.2007.09.006.
50. Wherry E.J., Barber D.L., Kaech S.M., Blattman J.N., Ahmed R. Antigen-independent memory CD8 T cells do not develop during chronic viral infection. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:16004-16009. 10.1073/pnas.0407192101.
51. Day C.L., Kaufmann D.E., Kiepiela P., Brown J.A., Moodley E.S., Reddy S., et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006, 443:350-354. 10.1038/nature05115.
52. Quigley M., Pereyra F., Nilsson B., Porichis F., Fonseca C., Eichbaum Q., et al. Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nat. Med. 2010, 16:1147-1151. 10.1038/nm.2232.
53. Larsson M., Shankar E.M., Che K.F., Saeidi A., Ellegård R., Barathan M., et al. Molecular signatures of T-cell inhibition in HIV-1 infection. Retrovirology 2013, 10:31. 10.1186/1742-4690-10-31.
54. Baitsch L., Baumgaertner P., Devêvre E., Raghav S.K., Legat A., Barba L., et al. Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients. J. Clin. Invest. 2011, 121:2350-2360. 10.1172/JCI46102.
55. Fourcade J., Sun Z., Pagliano O., Guillaume P., Luescher I.F., Sander C., et al. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res. 2012, 72:887-896. 10.1158/0008-5472.CAN-11-2637.
56. Zippelius A., Batard P., Rubio-Godoy V., Bioley G., Lienard D., Lejeune F., et al. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res. 2004, 64:2865-2873.
57. Legat A., Speiser D.E., Pircher H., Zehn D., Fuertes Marraco S.A. Inhibitory receptor expression depends more dominantly on differentiation and activation than "exhaustion" of human CD8 T Cells. Front. Immunol. 2013, 4:455. 10.3389/fimmu.2013.00455.
58. Radvanyi L.G., Bernatchez C., Zhang M., Fox P.S., Miller P., Chacon J., et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 2012, 18:6758-6770. 10.1158/1078-0432.CCR-12-1177.
59. Gros A., Robbins P.F., Yao X., Li Y.F., Turcotte S., Tran E., et al. PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. J. Clin. Invest. 2014, 124:2246-2259. 10.1172/JCI73639DS1.
60. Pentcheva-Hoang T., Egen J.G., Wojnoonski K., Allison J.P. B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity 2004, 21:401-413. 10.1016/j.immuni.2004.06.017.
61. Nirschl C.J., Drake C.G. Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clin. Cancer Res. 2013, 19:4917-4924. 10.1158/1078-0432.CCR-12-1972.
62. Rangachari M., Zhu C., Sakuishi K., Xiao S., Karman J., Chen A., et al. Bat3 promotes T cell responses and autoimmunity by repressing Tim-3-mediated cell death and exhaustion. Nat. Med. 2012, 18:1394-1400. 10.1038/nm.2871.
63. Huang Y.-H., Zhu C., Kondo Y., Anderson A.C., Gandhi A., Russell A., et al. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature 2015, 517:386-390. 10.1038/nature13848.
64. Derré L., Rivals J.-P., Jandus C., Pastor S., Rimoldi D., Romero P., et al. BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J. Clin. Invest. 2010, 120:157-167. 10.1172/JCI40070.
65. Johnston R.J., Comps-Agrar L., Hackney J., Yu X., Huseni M., Yang Y., et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell 2014, 26:923-937. 10.1016/j.ccell.2014.10.018.
66. Yu X., Harden K., Gonzalez L.C., Francesco M., Chiang E., Irving B., et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat. Immunol. 2008, 10:48-57. 10.1038/ni.1674.
67. Workman C.J., Dugger K.J., Vignali D.A.A. Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3. J. Immunol. 2002, 169:5392-5395.
68. Peggs K.S., Quezada S.A., Chambers C.A., Korman A.J., Allison J.P. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J. Exp. Med. 2009, 206:1717-1725. 10.1084/jem.20082492.
69. Takahashi T., Tagami T., Yamazaki S., Uede T., Shimizu J., Sakaguchi N., et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 2000, 192:303-310.
70. Read S., Malmström V., Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J. Exp. Med. 2000, 192:295-302.
71. Walker L.S.K., Sansom D.M. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat. Rev. Immunol. 2011, 11:852-863. 10.1038/nri3108.
72. Das R., Verma R., Sznol M., Boddupalli C.S., Gettinger S.N., Kluger H., et al. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J. Immunol. 2015, 194:950-959. 10.4049/jimmunol.1401686.
73. Grosso J.F., Jure-Kunkel M.N. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun. 2013, 13:5.
74. Vazquez-Cintron E.J., Monu N.R., Frey A.B. Tumor-induced disruption of proximal TCR-mediated signal transduction in tumor-infiltrating CD8+ lymphocytes inactivates antitumor effector phase. J. Immunol. 2010, 185:7133-7140. 10.4049/jimmunol.1001157.
75. Kyi C., Postow M.A. Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett. 2013, 588:368-376. 10.1016/j.febslet.2013.10.015.
76. Nguyen L.T., Ohashi P.S. Clinical blockade of PD1 and LAG3-potential mechanisms of action. Nat. Rev. Immunol. 2015, 15:45-56. 10.1038/nri3790.
77. Doering T.A., Crawford A., Angelosanto J.M., Paley M.A., Ziegler C.G., Wherry E.J. Network analysis reveals centrally connected genes and pathways involved in CD8. Immunity 2012, 37:1130-1144. 10.1016/j.immuni.2012.08.021.
78. Crawford A., Angelosanto J.M., Kao C., Doering T.A., Odorizzi P.M., Barnett B.E., et al. Molecular and transcriptional basis of CD4+ T cell dysfunction during chronic infection. Immunity 2014, 40:289-302. 10.1016/j.immuni.2014.01.005.
79. Crespo J., Sun H., Welling T.H., Tian Z., Zou W. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr. Opin. Immunol. 2013, 25:214-221. 10.1016/j.coi.2012.12.003.
80. Parish I.A., Rao S., Smyth G.K., Juelich T., Denyer G.S., Davey G.M., et al. The molecular signature of CD8+ T cells undergoing deletional tolerance. Blood 2009, 113:4575-4585. 10.1182/blood-2008-10-185223.
81. Macián F., García-Cózar F., Im S.-H., Horton H.F., Byrne M.C., Rao A. Transcriptional mechanisms underlying lymphocyte tolerance. Cell 2002, 109:719-731.
82. Shin H., Blackburn S.D., Intlekofer A.M., Kao C., Angelosanto J.M., Reiner S.L., et al. A role for the transcriptional repressor blimp-1 in CD8(+) T cell exhaustion during chronic viral infection. Immunity 2009, 31:309-320. 10.1016/j.immuni.2009.06.019.
83. Martinez G.J., Pereira R.M., Äijö T., Kim E.Y., Marangoni F., Pipkin M.E., et al. The transcription factor NFAT promotes exhaustion of activated CD8. Immunity 2015, 42:265-278. 10.1016/j.immuni.2015.01.006.
84. Intlekofer A.M., Takemoto N., Wherry E.J., Longworth S.A., Northrup J.T., Palanivel V.R., et al. Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin. Nat. Immunol. 2005, 6:1236-1244. 10.1038/ni1268.
85. Angelosanto J.M., Wherry E.J. Transcription factor regulation of CD8+ T-cell memory and exhaustion. Immunol. Rev. 2010, 236:167-175. 10.1111/j.1600-065X.2010.00927.x.
86. Best J.A., Blair D.A., Knell J., Yang E., Mayya V., Doedens A., et al. Transcriptional insights into the CD8+ T cell response to infection and memory T cell formation. Nat. Immunol. 2013, 14:404-412. 10.1038/ni.2536.
87. Grange M., Verdeil G., Arnoux F., Griffon A., Spicuglia S., Maurizio J., et al. Active STAT5 regulates T-bet and eomesodermin expression in CD8 T cells and imprints a T-bet-dependent Tc1 program with repressed IL-6/TGF-β1 signaling. J. Immunol. 2013, 191:3712-3724. 10.4049/jimmunol.1300319.
88. Curran M.A., Geiger T.L., Montalvo W., Kim M., Reiner S.L., Al-Shamkhani A., et al. Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of eomesodermin. J. Exp. Med. 2013, 210:743-755. 10.1084/jem.20121190.
89. Paley M.A., Kroy D.C., Odorizzi P.M., Johnnidis J.B., Dolfi D.V., Barnett B.E., et al. Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science (N. Y.) 2012, 338:1220-1225. 10.1126/science.1229620.
90. Buggert M., Tauriainen J., Yamamoto T., Frederiksen J., Ivarsson M.A., Michaëlsson J., et al. T-bet and eomes are differentially linked to the exhausted phenotype of CD8+ T cells in HIV infection. PLoS Pathog. 2014, 10:e1004251. 10.1371/journal.ppat.1004251.s008.
91. Berrien-Elliott M.M., Yuan J., Swier L.E., Jackson S.R., Chen C.L., Donlin M.J., et al. Checkpoint blockade immunotherapy relies on T-bet but not eomes to induce effector function in tumor-infiltrating CD8+ T cells. Cancer Immunol. Res. 2015, 3:116-124. 10.1158/2326-6066.CIR-14-0159.
92. Doedens A.L., Phan A.T., Stradner M.H., Fujimoto J.K., Nguyen J.V., Yang E., et al. Hypoxia-inducible factors enhance the effector responses of CD8(+) T cells to persistent antigen. Nat. Immunol. 2013, 14:1173-1182. 10.1038/ni.2714.
93. Stephen T.L., Rutkowski M.R., Allegrezza M.J., Perales-Puchalt A., Tesone A.J., Svoronos N., et al. Transforming growth factor beta-mediated suppression of antitumor T cells requires FoxP1 transcription factor expression. Immunity 2014, 41:427-439. 10.1016/j.immuni.2014.08.012.
94. Uyttenhove C., Pilotte L., Théate I., Stroobant V., Colau D., Parmentier N., et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 2003, 9:1269-1274. 10.1038/nm934.
95. Frumento G., Rotondo R., Tonetti M., Damonte G., Benatti U., Ferrara G.B. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J. Exp. Med. 2002, 196:459-468.
96. Opitz C.A., Litzenburger U.M., Sahm F., Ott M., Tritschler I., Trump S., et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 2011, 478:197-203. 10.1038/nature10491.
97. Ling W., Zhang J., Yuan Z., Ren G., Zhang L., Chen X., et al. Mesenchymal stem cells use IDO to regulate immunity in tumor microenvironment. Cancer Res. 2014, 74:1576-1587. 10.1158/0008-5472.CAN-13-1656.
98. Winans B., Nagari A., Chae M., Post C.M., Ko C.-I., Puga A., et al. Linking the aryl hydrocarbon receptor with altered DNA methylation patterns and developmentally induced aberrant antiviral CD8+ T cell responses. J. Immunol. 2015, 194:4446-4457. 10.4049/jimmunol.1402044.
99. Mascanfroni I.D., Takenaka M.C., Yeste A., Patel B., Wu Y., Kenison J.E., et al. Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1α. Nat. Med. 2015, 10.1038/nm.3868.
100. Huijbers I.J., Krimpenfort P., Chomez P., van der Valk M.A., Song J.-Y., Inderberg-Suso E.-M., et al. An inducible mouse model of melanoma expressing a defined tumor antigen. Cancer Res. 2006, 66:3278-3286. 10.1158/0008-5472.CAN-05-3216.
101. Soudja S.M., Wehbe M., Mas A., Chasson L., de Tenbossche C.P., Huijbers I., et al. Tumor-initiated inflammation overrides protective adaptive immunity in an induced melanoma model in mice. Cancer Res. 2010, 70:3515-3525. 10.1158/0008-5472.CAN-09-4354.
102. Giordano M., Roncagalli R., Bourdely P., Chasson L., Buferne M., Yamasaki S., et al. The tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20) imposes a brake on antitumor activity of CD8 T cells. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:11115-11120. 10.1073/pnas.1406259111.
103. Zhou P., Shaffer D.R., Alvarez Arias D.A., Nakazaki Y., Pos W., Torres A.J., et al. In vivo discovery of immunotherapy targets in the tumour microenvironment. Nature 2014, 506:52-57. 10.1038/nature12988.
104. Utzschneider D.T., Legat A., Fuertes Marraco S.A., Carrie L., Luescher I., Speiser D.E., et al. T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion. Nat. Immunol. 2013, 14:603-610. 10.1038/ni.2606.
105. Speiser D.E., Utzschneider D.T., Oberle S.G., Münz C., Romero P., Zehn D. T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion?. Nat. Rev. Immunol. 2014, 14:768-774. 10.1038/nri3740.
106. Galluzzi L., Vacchelli E., Bravo-San Pedro J.-M., Buqué A., Senovilla L., Baracco E.E., et al. Classification of current anticancer immunotherapies. Oncotarget 2014, 5:12472-12508.